Biometrix Technology., Inc. is striving to develop technology and products with the motto of ‘doing our best at every moment’ and is moving toward 'a company that leads the change in the diagnostic market'. In order to grow into a world-class diagnostic product company with an unwavering commitment, we will continue to develop technology and strengthen our core competencies to become a leader in the diagnostic market responsible for human health.

Biometrix Technology., Inc. was established in 2000, and has built a stable production line through constant technology development, innovation and process improvement to this day, adding to the enthusiasm and effort of me and all my employees, we are building biometrix technology even stronger.

Core technologies include 9G technology that arranges genes at regular intervals using molecular recognition of 9 guanine bases, and DAGON technology that can detect marker proteins up to very few levels of pg/ml. This is the world's first developed technology, which is a platform technology that can be applied to various gene and protein detection and commercializes and sells in vitro molecular diagnostic devices and reagents.

The cardiovascular disease monitoring products and early cancer molecular diagnostic products that we have developed this time are the food of our future. Using cardiovascular monitoring reagents for easy management of cardiovascular diseases, we entered the health examination market for cardiovascular prevention and management. And we are confident that Biometrix technology is leading the field of early-stage cancer screening, where no one has yet entered the market.

Biometrix Technology will continue to showcase the world's best cardiovascular and early cancer molecular diagnostic products and leap forward as a world-class health care company. We will show you the emergence of becoming a world-class health care company based on the spirit of challenge and passion for unlimited possibilities.

Thank you.

Taisun Kim, CEO of Biometrix Technology., Inc.